Gammoh Omar, Al-Smadi Ahmed, Shawagfeh Mohammad Q, Abadi Thani, Kasawneh Jawad, Malkawi Sukaina, Zein Sima
Faculty of Health Sciences, American University of Madaba, Amman, Jordan.
Princess Salma Faculty of Nursing, Department of Adult Health Nursing, Al al-Bayt University, Mafraq, Jordan.
Rev Recent Clin Trials. 2021;16(3):279-287. doi: 10.2174/1574887116666210201110507.
Similar anticonvulsants, such as gabapentin and pregabalin are recommended in neuropathic pain management, however little is known about their clinical differences in cases of low back pain. This paper aims to highlight some of the possible clinical differences between gabapentin and pregabalin in low back pain.
Patients with moderate to severe low back pain were recruited. Eligible patients were randomised to receive either pregabalin (300 mg/day)or gabapentin (800 mg/day) for six weeks. The primary outcome measure was pain intensity according to the Visual Analogue Score (VAS) at baseline and at six weeks. The secondary outcome measures were: anxiety, insomnia, fatigue and the self-rated (GCI), measured at baseline, second, fourth, and the sixth week.
A total of 64 patients, pregabalin group (n=28), gabapentin group (n=36) completed the study. While pregabalin group showed a significantly lower pain score (p=0.039). The gabapentin group showed significant improvement in anxiety (p=0.001), insomnia (p=0.001), general fatigue (p=0.009), physical fatigue (p=0.001), reduce activity (p=0.001), and mental fatigue (p=0.014) higher than that of pregabalin. No difference in (GCI) was seen at six weeks.
This is the first trial aimed at comparing gabapentin with pregabalin in NLBP. Although the results are preliminary, in our pilot study pregabalin was found to be superior in pain reduction, gabapentin demonstrated better effect on anxiety, insomnia and fatigue symptoms. The results are preliminary and studies with a larger sample size are still required.
在神经性疼痛管理中推荐使用类似的抗惊厥药，如加巴喷丁和普瑞巴林，然而对于它们在腰痛病例中的临床差异知之甚少。本文旨在突出加巴喷丁和普瑞巴林在腰痛方面一些可能的临床差异。
招募中度至重度腰痛患者。符合条件的患者被随机分配接受普瑞巴林（300毫克/天）或加巴喷丁（800毫克/天）治疗六周。主要结局指标是基线时和六周时根据视觉模拟评分（VAS）得出的疼痛强度。次要结局指标包括：在基线、第二周、第四周和第六周测量的焦虑、失眠、疲劳和自我评定的一般状况指数（GCI）。
共有64例患者，普瑞巴林组（n = 28）、加巴喷丁组（n = 36）完成了研究。普瑞巴林组的疼痛评分显著更低（p = 0.039）。加巴喷丁组在焦虑（p = 0.001）、失眠（p = 0.001）、总体疲劳（p = 0.009）、身体疲劳（p = 0.001）、活动减少（p = 0.001）和精神疲劳（p = 0.014）方面的改善程度高于普瑞巴林组。六周时在（GCI）方面未见差异。
这是第一项旨在比较加巴喷丁和普瑞巴林在非特异性腰痛中疗效的试验。尽管结果是初步的，但在我们的初步研究中发现普瑞巴林在减轻疼痛方面更具优势，加巴喷丁在焦虑、失眠和疲劳症状方面显示出更好的效果。结果是初步的，仍需要更大样本量的研究。
